UK Investor Magazine

The UK Investor Magazine is now live! Check out www.ukinvestormagazine.co.uk for valuable insights aimed at helping UK investors make smart financial choices. Our dedicated team will spotlight UK-listed companies and major global brands, exploring various asset types such as stocks, funds, forex, commodities, and crowdfunding options. We’ll also offer comparisons of top brokers to assist investors in choosing the best places for their investments. The magazine will be frequently updated with important market news to ensure our readers stay informed.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1011676

United Kingdom

#76328

Finance/Investing

#662

Traffic sources

Monthly visitors

Articles

AIM movers: Gelion fundraising following materials testing agreement and ex-dividends

1 week ago | ukinvestormagazine.co.uk | Andrew Hore

Lung cancer diagnostics developer LungLife AI (LON: LLAI) still plans to leave AIM following its US distribution deal, which requires shareholder approval. This will leave LungLife AI with the activities of running the LungLB test and collecting royalties. Circulogene will have exclusive rights to distribute and further development the LungLB lung cancer diagnostic in the US and the other countries it is involved in. It will also receive some of LungLife AI’s equipment.
AIM movers: Gear4Music acquires stock from former competitor and Sosandar downgraded

1 week ago | ukinvestormagazine.co.uk | Andrew Hore

Musical instruments retailer Gear4Music (LON: G4M) has acquired assets from the administrators of GAK (GAK.co.uk Ltd and The Guitar, Amp & Keyboard Centre Ltd). The stock purchased cost £600,000 but could have a value three times that figure. Gear4Music had been hit by discounting by GAK. There are no plans to use the GAK trading brand. There has been an improvement in trading with sales growth in double digits in recent weeks. The share price recovered 17% to 137.5p.
Jarvis Securities selling broker to Interactive Investor and winding up other operations

1 week ago | ukinvestormagazine.co.uk | Andrew Hore

Jarvis Securities (LON: JIM) is selling its execution only broking business to Interactive Investor for £11m and winding down its clearing and settlement operations. The share price slumped 58.1% to 18p. This is the lowest level since the end of 2006. The broking business generated £8.55m out of group revenues of £13.1m in 2023. Assets under administration ate £1.27bn.
AIM movers: Deltic Energy reports higher Selene gas resources and tough trading for Billington, but order book strong

1 week ago | ukinvestormagazine.co.uk | Andrew Hore

North Sea gas project developer Deltic Energy (LON: DELT) says estimates of gross 2C contingent resources at the Selene gas project, where Deltic Energy has a 25% interest, increased by one-third to 174bcf and its share of post-tax NPV10 estimate is $83m met at 80p/therm. Modelling suggests enhanced production potential from the B-sand interval. A final investment decision could happen in early 2027. The share price is one-quarter higher at 5p.
Impressive Rockwood Strategic track record

1 week ago | ukinvestormagazine.co.uk | Andrew Hore

Investment company Rockwood Strategic (LON: RKW) has an excellent track record of investing in undervalued companies and growing its NAV. The latest trading statement shows that the momentum is being maintained. It is a good idea to take note of where it is investing. Rockwood Strategic identifies undervalued and underperforming smaller quoted companies. It gets involved with the companies and their strategies with a three-to-five-year outlook.
AIM movers: Disappointment for Pantheon Resources and new distributor for Distil

2 weeks ago | ukinvestormagazine.co.uk | Andrew Hore

Spirits brands owner Distil (LON: DIS) has secured a US distributor to relaunch Blavod Black Vodka in the US. AIKO Importers has a network of 185 distribution partners in the US, Canada and Puerto Rico and relationships with retailers. Blavod Black Vodka is the company’s original brand and shipments should start in June. Distil is assuming that tariffs remain in place and that they are manageable. The share price rebounded 32.1% to 0.0925p.
AIM weekly movers:Induction Healthcare recommends bid

2 weeks ago | ukinvestormagazine.co.uk | Andrew Hore

Induction Healthcare (LON: INHC) is recommending a 10p/share cash bid from VitalHub Corp. That values the digital healthcare technology company at £9.7m. The flotation in 2019 raised £14.6m at 115p/share. The share price recovered 58.3% to 9.5p. Atome (LON: ATOM) has signed a definitive Engineering, Procurement and Construction (EPC) contract with Casale for its Villeta green fertiliser project in Paraguay.
Aquis weekly movers: EDX Medical launching testicular cancer test

2 weeks ago | ukinvestormagazine.co.uk | Andrew Hore

EDX Medical Group (LON: EDX) is launching TC100, a highly accurate early detection test for testicular cancer. A blood sample is assessed. There have been more than 30 study reports on the test. The share price improved 17.4% to 13.5p. BWA Group (LON: BWAP) published an updated inferred mineral resource for the Dehane heavy mineral sands project in Cameroon of 4.2 million tonnes at 3.5% THM cut-off, comprising grades of ilmenite at 0.99%, kyanite at 1.54%, rutile at 0.13% and zircon at 0.11%.
AIM movers: Greatland Gold progresses to ASX listing and Niox bid not happening

2 weeks ago | ukinvestormagazine.co.uk | Andrew Hore

Greatland Gold (LON: GGP) is changing the domicile of the holding company to Australia. This will be called Greatland Resources Ltd and is part of the process of gaining a listing on ASX. The AIM quotation will be retained. The share price rose 16.7% to 14p. Oracle Power (LON: ORCP) has published further assay results for the Northern Zone Intrusive Hosted gold project and there some significant gold intercepts with grades of up to 1.94g/t gold. All eleven holes have intersected gold mineralisation.
AIM movers: Verici Dx receives reimbursement price for Tutivia and ex-dividends

2 weeks ago | ukinvestormagazine.co.uk | Andrew Hore

Organ transplant diagnostics developer Verici Dx (LON: VRCI) has received the local coverage determination for Tutivia reimbursement, so revenues on the tests can start to be recognised. There were 292 tests ordered in the first quarter of 2025 and price has been set at $2,650 each. The annual global market is 100,000 patients. Singer previously cut 2025 estimated revenues from $11.6m to $4.4m. A fundraising is expected by June.